ADXS-503

News alerts, weekly reports and conference planners

Company:

Ayala Pharma

Drug class:

T-cell stimulant

Related drugs:

‹

›

6ms

Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)

P1/2, N=24, Completed, Advaxis, Inc. | Recruiting --> Completed | N=74 --> 24

6 months ago

Trial completion • Enrollment change • Combination therapy • Metastases

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)

Keytruda (pembrolizumab) • ADXS-503

over3years

[VIRTUAL] Evaluation of total PD-1 expression using multi-color flow cytometry in metastatic non-small Cell lung cancer patients treated with multi-neoantigen vector (ADXS-503) alone and in combination of pembrolizumab to assess T-cell & T-cell memory subsets (AACR 2021)

ADXS-503 (A503) is an off-the-shelf, attenuated Listeria monocytogenes (Lm)-based immunotherapy bioengineered to elicit potent T-cell responses against 22 tumor antigens commonly found in NSCLC. This novel assay will facilitate the evaluation of total PD-1 expression as a pharmacodynamic biomarker in T-cells when PD-1 blockade is being used. These results also support that combination of ADXS-503 with PD-1 blockade could lead to enhancement of efficacy of anti-tumor immunotherapy.

over 3 years ago

Clinical • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule)

PD-L1 expression • PD-1 expression

Keytruda (pembrolizumab) • ADXS-503